Pliant Therapeutics Inc Net Income per Employee (PLRX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Pliant Therapeutics Inc   (NASDAQ: PLRX)
 

Pliant Therapeutics Inc Net Income per Employee

PLRX's Quarterly Results, Trends, Rankings, Statistics
Pliant Therapeutics Inc recorded a cumulative net loss of $-92 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 365 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4041, from total ranking in previous quarter at 4651.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PLRX Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,883,449 -2,310,571 -3,047,837 -3,581,612 -4,223,694
PLRX's Total Ranking # 4041 # 4651 # 4304 # 4453 # 4440
Seq. Net Income Change - - - - -

PLRX Company Profile >> Back to PLRX Efficiency Comparisons >> Compare PLRX Net Income per Employee to its Competitors

PLRX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 366
Healthcare Sector # 808
Overall Market # 4041

Net Income per Employee Statistics
High Average Low
$ -346,959 $ -2,636,744 $ -4,479,898
(Jun 30 2020)   (Mar 31 2025)




  News about Pliant Therapeutics Inc Income per employee

Navigating the Complex Terrain of Bexotegrast Pliant Therapeutics Halts BEACON-IPF Trial Amid Promising Indications

In the constantly shifting landscape of pharmaceutical research, Pliant Therapeutics, Inc., based in South San Francisco, has recently made significant strides, only to find themselves pausing for reassessment. The company announced that it has discontinued its BEACON-IPF Phase 2b trial, which was evaluating the efficacy of bexotegrast in patients suffering from idiopathic pulmonary fibrosis (IPF).The decision to halt the trial was made after a prespecified data review and recommendation by an independent Data Safety Monitoring Board (DSMB), corroborated by a secondary review from an external expert panel. The crux of the issue lay in an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups. Despite this, some encouraging signs emerged, notably early evidence of efficacy concerning the forced vital capacity (FVC) endpoint, a crucial measure for patients with pulmonary diseases.

Pliant Therapeutics Faces Competitive Pressure as Q1 2025 Financial Results Reveal Stagnant Growth and Upcoming Cli...

Pliant Therapeutics Provides Corporate Update and Q1 2025 Financial Results Amid Competitive Landscape Challenges Pliant Therapeutics Inc. has released its corporate update alongside the financial results for the first quarter of 2025. With the ongoing activities focused on the closeout of the BEACON-IPF clinical trial, the company remains on track to announce topline data in the second quarter of 2025. This important milestone is expected to significantly impact the company s growth trajectory and investor sentiment moving forward.Financially, Pliant reported a year-on-year revenue growth of 0% in the fourth quarter of 2024. This revenue performance is notably below the average industry benchmark of 9.8% achieved by its competitors within the same period. This comparison not only highlights the challenges Pliant is facing but also emphasizes the need for appropriate strategic adjustments to enhance its financial standing in the competitive biopharmaceutical arena.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-04T10:37:16+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.